Phase 3 Migraine Trial, Recruiting NCT05711394 Sponsor: AbbVie Condition: Migraine
Back to Migraine

Phase 3 Migraine Trial, Recruiting

NCT05711394
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your child weighs at least 44 lbs (20 kg) and less than 298 lbs (135 kg).
  • Your child has had episodic migraines (with or without visual or sensory warning signs called "aura") for at least 6 months.
  • During the 28-day tracking period before the trial, your child had between 4 and 14 migraine days, and fewer than 15 headache days total.
  • For a specific part of the study looking at how the body processes the medication, your child must be between 6 and 11 years old, have a history of migraines, and the doctor must agree that preventive migraine treatment is appropriate for them.

Who may not be able to join:

  • Your child has a history of certain specific types of migraine, including migraines that affect brainstem function, migraines that cause temporary paralysis on one side of the body (hemiplegic migraine), or migraines that affect vision in one eye (retinal migraine) (confirm with trial site).
  • Your child currently has chronic migraine, meaning they have very frequent migraines on most days of the month (confirm with trial site).
  • Your child has been diagnosed with certain other types of persistent or severe head pain conditions, such as daily non-stop headaches, cluster headaches, or nerve-related facial pain (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
1 May 2023
Est. completion
1 March 2028

Where this trial is recruiting

🇧🇪 Belgium 🇨🇦 Canada 🇩🇰 Denmark 🇫🇷 France 🇭🇺 Hungary 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇳🇱 Netherlands 🇵🇱 Poland Puerto Rico 🇷🇴 Romania 🇪🇸 Spain 🇸🇪 Sweden 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Change from Baseline in Mean Monthly Migraine Days; Number of Participants Experiencing Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov